R&G PharmaStudies Co. Ltd. A (301333) — Cash Flow Quality Index
R&G PharmaStudies Co. Ltd. A (301333) has a Cash Flow Quality Index of 1.19x as of June 2022. Operating cash flow of CN¥40.98 Million exceeds net income of CN¥34.56 Million, indicating high earnings quality where cash backs reported profits. Explore 301333 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
R&G PharmaStudies Co. Ltd. A Cash Flow Quality Index (2019–2025)
Historical Cash Flow Quality Index for R&G PharmaStudies Co. Ltd. A across 7 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see R&G PharmaStudies Co. Ltd. A cash flow conversion.
Annual Cash Flow Quality Index for R&G PharmaStudies Co. Ltd. A (2019–2025)
Year-by-year earnings quality comparison for R&G PharmaStudies Co. Ltd. A.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.83x | CN¥114.20 Million | CN¥136.90 Million | ▼ -24.4% |
| 2024 | 1.10x | CN¥154.76 Million | CN¥140.22 Million | ▼ -6.8% |
| 2023 | 1.18x | CN¥192.56 Million | CN¥162.53 Million | ▲ +3.2% |
| 2022 | 1.15x | CN¥130.47 Million | CN¥113.59 Million | ▼ -0.5% |
| 2021 | 1.15x | CN¥114.57 Million | CN¥99.24 Million | ▲ +119.5% |
| 2020 | 0.53x | CN¥44.10 Million | CN¥83.84 Million | ▼ -58.0% |
| 2019 | 1.25x | CN¥103.48 Million | CN¥82.63 Million | — |